Hypothalamic Sirt1 Regulates Food Intake in a Rodent Model System Authors: Işin Çakir, Mario Perello, Omar Lansari, Norma J. Messier, Charles A. Vaslet, Eduardo A. Nillni Published: 2009, PLOS ONE DOI: 10.1371/journal.pone.0008322 ABSTRACT Sirt1 is an evolutionarily conserved NAD + dependent deacetylase involved in a wide range of processes including cellular differentiation, apoptosis, as well as metabolism, and aging. In this study, we investigated the role of hypothalamic Sirt1 in energy balance. Pharmacological inhibition or siRNA mediated knock down of hypothalamic Sirt1 showed to decrease food intake and body weight gain. Central administration of a specific melanocortin antagonist, SHU9119, reversed the anorectic effect of hypothalamic Sirt1 inhibition, suggesting that Sirt1 regulates food intake through the central melanocortin signaling. We also showed that fasting increases hypothalamic Sirt1 expression and decreases FoxO1 (Forkhead transcription factor) acetylation suggesting that Sirt1 regulates the central melanocortin system in a FoxO1 dependent manner. In addition, hypothalamic Sirt1 showed to regulate S6K signaling such that inhibition of the fasting induced Sirt1 activity results in up-regulation of the S6K pathway. Thus, this is the first study providing a novel role for the hypothalamic Sirt1 in the regulation of food intake and body weight. Given the role of Sirt1 in several peripheral tissues and hypothalamus, potential therapies centered on Sirt1 regulation might provide promising therapies in the treatment of metabolic diseases including obesity. INTRODUCTION Sirt1 is an evolutionarily conserved NAD + -dependent deacetylase involved in a wide range of metabolic processes in the periphery [1] . In the liver, Sirt1 deacetylates and activates the transcriptional co-activator PGC1-alpha and the transcription factor FoxO1 to promote gluconeogenesis [2] , [3] . In the adipose tissue, Sirt1 triggers fat mobilization by inhibiting peroxisome proliferator-activated receptor (PPAR-gamma), and in the pancreas repression of the uncoupling protein 2 (UCP2) by Sirt1 increases insulin secretion [1] . Sirt1 expression as well as its activity is nutrient sensitive. For example, in the liver, the Sirt1 protein level increases upon fasting [3] and decreases by high fat diet [4] . Sirt1 action in the central nervous system has been studied as well. Sirt1 has neuroprotective effects. For example, increased nuclear NAD biosynthesis and Sirt1 activation are linked to axonal protection [5] , and hippocampus over expression of Sirt1 provides protection against neurodegeneration in a mouse model of Alzheimer's disease [6] . Sirt1 showed to be important in the regulation of stem cells to generate either astroglial lineage or the neuronal lineage [7] . At a global scale Sirt1 target genes in the mouse brain are deregulated by aging. This situation (at the gene expression level) can be reversed by specific over expression of central Sirt1 [8] . Brain Sirt1 expression increases by caloric restriction [9] , and fasting was shown to increase brain Sirt1 protein content specifically in the hypothalamus [10] . A better understanding of hypothalamic Sirt1 action is of crucial importance since the hypothalamus is the primary brain center that interprets adiposity or nutrient related inputs to regulate energy homeostasis. Specifically, the anorexigenic proopiomelanocortin (POMC) neurons and the orexigenic NPY/AgRP neurons in the arcuate nucleus (ARC) of the hypothalamus are the major regulators of feeding and energy expenditure [11] . Although the Sirt1 expression in POMC neurons has been reported [10] , its functional role in the hypothalamus has not been determined. Hypothalamic control of food intake and body weight involves the action of metabolic sensors including the mammalian target of rapamycin (mTOR) [12] and AMP activated kinase (AMPK) [13] . Because of its dependence on NAD + , Sirt1 also functions as a metabolic sensor [14] . Therefore, we hypothesized that hypothalamic Sirt1 represents another metabolic factor controlling food intake. Using the rat as a physiological in vivo model we found that ablation of Sirt1 activity or knocking-down Sirt1 gene expression at the hypothalamic level resulted in decreased food intake and body weight gain. Blocking the melanocortin receptors with the melanocortin antagonist SHU9119 attenuated the anorectic effect of Sirt1 inhibition. Fasting increased hypothalamic NAD + levels and Sirt1 protein content. Inhibition of hypothalamic Sirt1 activity reversed the fasting induced decrease of FoxO1 acetylation, and resulted in increased POMC and decreased AgRP expressions. Regulation of POMC by Sirt1 depends on FoxO1 as shown utilizing in vivo and in vitro approaches. We also present data showing that hypothalamic Sirt1 regulates S6K signaling. Thus, targeting central Sirt1 signaling may show promise for the treatment of obesity and the associated disorders. RESULTS To study the potential role of hypothalamic Sirt1 in energy balance we first determined its expression in the rat hypothalamus. Immunohistochemical (IHC) staining revealed a nuclear Sirt1 expression in certain hypothalamic centers involved in energy homeostasis, namely the ARC and paraventricular nucleus (PVN) of the hypothalamus ( Figure S1A ). By immunoblotting analysis, we also confirmed the presence of Sirt1 in the ARC, PVN, primary neurons, and in the mouse corticotropic AtT20 cell line ( Figure S1B ) (see below). As recently described for the mouse brain [10] , Sirt1 expression is present in other brain areas such as the hippocampal formation and cortex ( Figure S1C ). We next wanted to determine if modulating Sirt1 activity or its expression would effect food intake and body weight of adult rats. To block Sirt1 enzymatic activity we used a potent Sirt1 inhibitor [15] . This compound (EX-527) is a small, selective inhibitor of SIRT1 that does not inhibit histone deacetylases and is specific for Sirt1 over other sirtuin family members [16] , [17] . Intracerebro-ventricular (ICV) administration of EX-527 for 24 ( Figure S1D , left and middle panels) or 48 hours ( Figure 1A left and middle panels) in fasted rats resulted in a decreased in food intake accompanied by a reduced body weight gain. Both the food intake and body weight changes induced by EX527 were Sirt1 specific because both parameters were reversed by co-administration of a Sirt1 activator [18] (Sirt1 activator 3, or SA3) at a dose, which alone did not change either food intake or weight gain ( Figure 1A ). Induction of hypothalamic Sirt1 activity by ICV infusion of SA3 to re-fed rats ( Figure S1D , right panel) resulted in increased short-term food intake ( Figure 1A , right). To confirm the specificity of pharmacological Sirt1 inhibition, and to observe whether the acute manipulation of Sirt1 activity could be recapitulated in the long-term, we knocked down Sirt1 expression by infusing Sirt1 specific siRNAs directly into the ARC ( Figure S1F ). Consequently, Sirt1 expression was knocked-down 40% at the protein level ( Figure S1E ), which was confirmed by the decreased number of Sirt1 positive ARC nuclei ( Figure S1F, G ). Rats with diminished ARC Sirt1 protein consumed less food ( Figure 1B , left), and gained less weight compared to the control group ( Figure 1B , right). . (A) Pharmacological inhibition of Sirt1 decreases food intake (left) and body weight gain (middle) in fasted rats, whereas activation of Sirt1 increases food intake (right) in re-fed rats. n = 8–9, per treatment, and per group. ( B) Food intake (left) and body weight gain (right) decreases by knocking down Sirt1 expression specifically in the ARC. n = 6–7, per treatment. ( C) (Left) Effect of co-administration of EX527 and SHU9119 on food intake. Animals were treated the same way as in ( A) . Food intake was measured overnight for a period of 16 hours. (Right) Effect of co-administration of EX527 and SHU9119 on body weight change. Same animals were weighed one hour before dark cycle, and in the morning. n = 5 per treatment. ( D) Fasted rats were icv infused with DMSO (vehicle) or EX-527 as described in ( A) . One hour after second icv infusion (49-hour of fasting) rats were sacrificed. Blood was collected at the time of decapitation. Plasma T3 and T4 was determined by RIA. (DM, DMSO; EX, EX-527; SHU, SHU9119; SA3, Sirt1 Activator 3). Values are the mean±SEM. *, 0.01